Genetic profiling suggested an enrichment of tumor promoting gene sets (including CDK4, RBM10 and GLI1) in the EGFRMut/MDM2Amp cohort (Fig. 1D), while these candidate genes did not directly affect cell proliferation or cell death programs, we therefore concluded that MDM2 may not regulate sensitivity to Osimertinib at transcriptional level. Here, CDK4 is linked to neoplasm.